Claims for Patent: 8,802,881

Summary for Patent: 8,802,881

Title:	Benzo lipoxin analogues
Abstract:	Benzolipoxin analogs, methods of their preparation and pharmaceutical compositions containing the compounds are provided. The compounds and compositions are useful in methods for treatment of various diseases, including, inflammation, autoimmune disease and abnormal cell proliferation.
Inventor(s):	Petasis; Nicos A. (Hacienda Heights, CA)
Assignee:	University of Southern California (Los Angeles, CA)
Application Number:	13/372,029
Patent Claims:	1. A compound having a structural and stereochemical formula selected from the group consisting of: ##STR00024## wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or OM, wherein M is an ammonium, tetra-alkyl ammonium, sodium, potassium, magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, or sulfonamide; R.sup.a-R.sup.c are each independently hydrogen, alkyl, aryl, acyl or alkoxyacyl; n is zero, one or two; and m is one or two, or a pharmaceutically acceptable salt thereof. 2. The compound of claim 1, wherein W is alkyl. 3. The compound of claim 1, wherein W is butyl. 4. The compound of claim 1, wherein W is aryloxy. 5. The compound of claim 1, wherein A is hydroxy or alkoxy. 6. The compound of claim 1, wherein R.sup.a, R.sup.b, and R.sup.c are each hydrogen. 7. A compound having a structural and stereochemical formula selected from the group consisting of: ##STR00025## wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or OM, wherein M is an ammonium, tetra-alkyl ammonium, sodium, potassium, magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, or sulfonamide; or a pharmaceutically acceptable salt thereof. 8. The compound of claim 7, wherein W is alkyl. 9. The compound of claim 7, wherein W is butyl. 10. The compound of claim 7, wherein W is aryloxy. 11. The compound of claim 7, wherein A is hydroxy or alkoxy. 12. The compound of claim 7, having a structural and stereochemical formula: ##STR00026## wherein: R is hydrogen, alkyl, cycloalkyl or aryl or a pharmaceutically acceptable salt thereof. 13. The compound of claim 12, wherein R is methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl or isobutyl. 14. The compound of claim 12, wherein R is hydrogen. 15. A compound having a structural and stereochemical formula selected from the group consisting of: ##STR00027## wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or OM, wherein M is an ammonium, tetra-alkyl ammonium, sodium, potassium, magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, or sulfonamide; R.sup.a-R.sup.c are each independently hydrogen, alkyl, aryl, acyl or alkoxyacyl; m is one or two, or a pharmaceutically acceptable salt thereof. 16. A compound having a structural and stereochemical formula selected from the group consisting of: ##STR00028## wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or OM, wherein M is an ammonium, tetra-alkyl ammonium, sodium, potassium, magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, or sulfonamide; or a pharmaceutically acceptable salt thereof. 17. A pharmaceutical composition comprising a compound according to claim 1 and a pharmaceutically acceptable carrier. 18. The pharmaceutical composition of claim 17 wherein the formulation is suitable for topical administration. 19. The pharmaceutical composition of claim 17 wherein the formulation is a cream, gel, ointment, emulsion, solution, elixir, lotion, suspension, tincture, paste, foam, aerosol, irrigation, or spray. 20. The pharmaceutical composition of claim 17 wherein the formulation is a gel, emulsion, solution, or paste. 21. The pharmaceutical composition of claim 17 wherein the formulation further comprises one or more of the group consisting of: a sterile diluent; antimicrobial agent; antioxidant; chelating agent; buffer; and agent for the adjustment of tonicity. 22. The pharmaceutical composition of claim 17 wherein the formulation is suitable for topical administration to the eye. 23. The pharmaceutical composition of claim 17 wherein the formulation is suitable for topical administration to the skin and mucous. 24. The pharmaceutical composition of claim 17 wherein the formulation is suitable for transdermal delivery. 25. The pharmaceutical composition of claim 17 wherein the formulation is suitable for inhalation therapies. 26. The pharmaceutical composition of claim 17 wherein the formulation is a nasal solution. 27. The pharmaceutical composition of claim 17 wherein R.sup.a, R.sup.b, and R.sup.c are each hydrogen. 28. The pharmaceutical composition of claim 17 wherein W is alkyl. 29. The pharmaceutical composition of claim 17 wherein W is butyl. 30. The pharmaceutical composition of claim 17 wherein W is aryloxy. 31. The pharmaceutical composition of claim 17 wherein A is hydroxy or alkoxy. 32. A pharmaceutical composition comprising a compound according to claim 7 and a pharmaceutically acceptable carrier. 33. The pharmaceutical composition of claim 32 wherein W is alkyl. 34. The pharmaceutical composition of claim 32 wherein W is butyl. 35. The pharmaceutical composition of claim 32 wherein W is aryloxy. 36. The pharmaceutical composition of claim 32 wherein A is hydroxy or alkoxy. 37. A pharmaceutical composition comprising a compound having a structural and stereochemical formula selected from the group consisting of: ##STR00029## wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or OM, wherein M is an ammonium, tetra-alkyl ammonium, sodium, potassium, magnesium or zinc cation; or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier. 38. The pharmaceutical composition of claim 37, wherein A is hydroxy. 39. A pharmaceutical composition comprising a compound according to claim 37, wherein A is an alkoxy group OR, wherein R is methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl or isobutyl. 40. A pharmaceutical composition according to claim 39, wherein R is methyl. 41. A method of ameliorating or treating a disease or condition associated with inflammation, autoimmune diseases or abnormal cell proliferation, the method comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition of claim 37. 42. The method of claim 41, wherein the disease or condition is neutrophil-mediated inflammation or neutrophil-mediated damage. 43. The method of claim 41, wherein the disease or condition is inflammatory ophthalmic disease. 44. The method of claim 41, wherein the disease or condition is arthritis, asthma or psoriasis. 45. The method of claim 41, wherein the disease or condition is inflammatory bowel disease, periodontal disease, or systemic dermatomyositis. 46. The method of claim 41, wherein the disease associated with abnormal cell proliferation is a non-small cell lung cancer, head and neck squamous cancers, colorectal cancer, prostate cancer, breast cancer, acute lymphocytic leukemia, adult acute myeloid leukemia, adult non-Hodgkin's lymphoma, brain tumors, cervical cancers, childhood cancers, childhood sarcoma, chronic lymphocytic leukemia, chronic myeloid leukemia, esophageal cancer, hairy cell leukemia, kidney cancer, liver cancer, multiple myeloma, neuroblastoma, oral cancer, pancreatic cancer, primary central nervous system lymphoma, skin cancer, and small-cell lung cancer. 47. The method of claim 41, wherein the disease associated with abnormal cell proliferation is colorectal cancer, breast cancer or brain tumors. 48. An article of manufacture, comprising packaging material, a compound of claim 1, or a pharmaceutically acceptable salt thereof contained within the packaging material, and a label that indicates that the compound or pharmaceutically acceptable salt thereof is used for treatment or amelioration of one or more symptoms associated with a disease or condition associated inflammation, autoimmune diseases or abnormal cell proliferation. 49. The article of manufacture of claim 48, wherein the disease or condition is neutrophil-mediated inflammation or neutrophil-mediated damage. 50. The article of manufacture of claim 48, wherein the disease or condition is inflammatory ophthalmic disease. 51. A method of ameliorating or treating a disease or condition associated with inflammation, autoimmune diseases or abnormal cell proliferation, the method comprising administering to a subject a therapeutically effective amount of a topical formulation comprising a compound of claim 1, and a pharmaceutically acceptable carrier. 52. The method of claim 51, wherein the disease or condition is neutrophil-mediated inflammation or neutrophil-mediated damage. 53. The method of claim 51, wherein the disease or condition is inflammatory ophthalmic disease. 54. The method of claim 51 wherein the formulation is suitable for topical administration to the eye. 55. The method of claim 51 wherein the formulation is suitable for topical administration to the skin and mucous membranes, including transdermal delivery. 56. A substantially diastereomerically pure, optical isomer of a compound selected from the group consisting of: ##STR00030## ##STR00031## wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or OM, wherein M is an ammonium, tetra-alkyl ammonium, sodium, potassium, magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, or sulfonamide; R.sup.a-R.sup.c are each independently hydrogen, alkyl, aryl, acyl or alkoxyacyl; n is zero, one or two; and m is one or two, or a pharmaceutically acceptable salt thereof. 57. The substantially diastereomerically pure, optical isomer of claim 56, where the compound is: ##STR00032## 58. The substantially diastereomerically pure, optical isomer of claim 57, where the compound is: ##STR00033## or a pharmaceutically acceptable salt thereof. 59. A substantially diastereomerically pure, optical isomer of a compound with the formula: ##STR00034## 60. A substantially diastereomerically pure, optical isomer of a compound with the formula: ##STR00035## wherein: A is hydroxy, alkoxy, aryloxy, amino, alkylamino, dialkylamino or OM, wherein M is an ammonium, tetra-alkyl ammonium, sodium, potassium, magnesium or zinc cation; W is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl, halo, hydroxy, alkoxy, aryloxy, carboxy, amino, alkylamino, dialkylamino, acylamino, carboxamido, or sulfonamide; R.sup.a-R.sup.c are each independently hydrogen, alkyl, aryl, acyl or alkoxyacyl; and m is one or two, or a pharmaceutically acceptable salt thereof. 61. The substantially diastereomerically pure, optical isomer of claim 60, where the compound is: ##STR00036## wherein: R is hydrogen, alkyl, cycloalkyl or aryl or a pharmaceutically acceptable salt thereof. 62. The compound of claim 61, wherein R is methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl or isobutyl. 63. The compound of claim 61, wherein R is hydrogen. 64. The substantially diastereomerically pure, optical isomer of claim 60, where the compound is: ##STR00037## or a pharmaceutically acceptable salt thereof. 65. A substantially diastereomerically pure, optical isomer of a compound with the formula: ##STR00038## or a pharmaceutically acceptable salt thereof. 66. A pharmaceutical composition comprising a compound according to claim 15 and a pharmaceutically acceptable carrier. 67. A pharmaceutical composition comprising a compound according to claim 16 and a pharmaceutically acceptable carrier. 68. A pharmaceutical composition comprising a compound according to claim 56 and a pharmaceutically acceptable carrier. 69. A pharmaceutical composition comprising a compound according to claim 60 and a pharmaceutically acceptable carrier. 70. A pharmaceutical composition comprising a compound according to claim 59 and a pharmaceutically acceptable carrier. 71. A method of ameliorating or treating a disease or condition associated with inflammation, autoimmune diseases or abnormal cell proliferation, the method comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition of claim 70. 72. The method of claim 71, wherein the disease or condition is neutrophil-mediated inflammation or neutrophil-mediated damage. 73. The method of claim 71, wherein the disease or condition is inflammatory ophthalmic disease. 74. The method of claim 71, wherein the disease or condition is arthritis, asthma or psoriasis. 75. The method of claim 71, wherein the disease or condition is inflammatory bowel disease, periodontal disease, or systemic dermatomyositis. 76. The method of claim 71, wherein the disease associated with abnormal cell proliferation is a non-small cell lung cancer, head and neck squamous cancers, colorectal cancer, prostate cancer, breast cancer, acute lymphocytic leukemia, adult acute myeloid leukemia, adult non-Hodgkin's lymphoma, brain tumors, cervical cancers, childhood cancers, childhood sarcoma, chronic lymphocytic leukemia, chronic myeloid leukemia, esophageal cancer, hairy cell leukemia, kidney cancer, liver cancer, multiple myeloma, neuroblastoma, oral cancer, pancreatic cancer, primary central nervous system lymphoma, skin cancer, and small-cell lung cancer. 77. The method of claim 71, wherein the disease associated with abnormal cell proliferation is colorectal cancer, breast cancer or brain tumors. 78. A pharmaceutical composition comprising a compound according to claim 65 and a pharmaceutically acceptable carrier. 79. A method of ameliorating or treating a disease or condition associated with inflammation, autoimmune diseases or abnormal cell proliferation, the method comprising administering to a subject a therapeutically effective amount of a pharmaceutical composition of claim 78.

Details for Patent 8,802,881

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2023-09-10